Avita Medical's Recell Go Mini Receives FDA Approval, Stock Surges Over 6%

Avita Medical's stock displayed a performance increase of over 6% during market hours on Monday, following the company's announcement that the pre-launch approval of its Recell Go mini had been granted by the U.S. Food and Drug Administration (FDA).

This product serves as an addition to the company's skin repair product range. The Recell Go mini is a disposable cartridge specifically designed to treat smaller wounds of up to 480 square centimeters.

Avita Medical stated that the launch of the Recell Go mini will initially begin with trauma and burn centers that currently treat smaller wounds.

"The FDA approval for Recell Go mini enhances our ability to provide clinicians with purpose-built solutions to meet the diverse needs of patients with full-thickness wounds," said Avita Medical's CEO Jim Corbett in a press release.

The company expects this launch to commence in the first quarter of 2025.